Nobivac Respira Bb vet. suspension for injection for dogs

Authorised

- Bordetella bronchiseptica, strain Bb7 92932, fimbriae

Product identification

Medicine name:
Nobivac Respira Bb vet. suspension for injection for dogs
Nobivac Respira Bb suspensija injekcijām suņiem

Active substance:
Bordetella bronchiseptica, strain Bb7 92932, fimbriae

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Bordetella bronchiseptica, strain Bb7 92932, fimbriae
88.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI06AE02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Latvia

Package description:
Available only in Latvian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
27/10/2020

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Food And Veterinary Service

Authorisation number:
V/DCP/20/0056

Date of authorisation status change:
27/10/2020

Reference member state:
Denmark

Procedure number:
DK/V/0123/002

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

PI.pdf